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BACKGROUND: Cervical cancer (CC) remains a leading cause of gynaecological cancer-related mortality world
wide and constitutes the third most common malignancy in women. The RAIDs consortium (http://www.
raids-fp7.eu/) conducted a prospective European study [BioRAIDs (NCT02428842)] with the objective to
stratify CC patients for innovative treatments. A “metagene” of genomic markers in the PI3K pathway and
epigenetic regulators had been previously associated with poor outcome [2].
METHODS: To detect new, more specific, targets for treatment of patients who resist standard chemo-radiation,
a high-dimensional Cox model was applied to define dominant molecular variants, copy number variations,
and reverse phase protein arrays (RPPA).
FINDINGS: Survival analysis on 89 patients with all omics data available, suggested loss-of-function (LOF) or
activating molecular alterations in nine genes to be candidate biomarkers for worse prognosis in patients
treated by chemo-radiation while LOF of ATRX, MED13 as well as CASP8 were associated with better progno-
sis. When protein expression data by RPPA were factored in, the supposedly low molecular weight and
nuclear form, of beta-catenin, phosphorylated in Ser552 (pb-Cat552), ranked highest for good prognosis,
while pb-Cat675 was associated with worse prognosis.
INTERPRETATION: These findings call for molecularly targeted treatments involving p53, Wnt pathway, PI3K
pathway, and epigenetic regulator genes. Pb-Cat552 and pb-Cat675 may be useful biomarkers to predict out-
come to chemo-radiation, which targets the DNA repair axis.
FUNDING: European Union’s Seventh Program for research, technological development and demonstration
(agreement N°304,810), the Fondation ARC pour la recherche contre le cancer.
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RESEARCH IN CONTEXT
The molecular landscape of cervical cancer [1,2] similarly to
that of squamous cell carcinoma of head and neck [3,4] has
been characterized and actionable or targetable genomic altera-
tions have been identified. However, single targeted therapies
have very limited activity in unselected patients. Even in
selected patients [5], activity is limited, owing to the fact that
advanced disease has multiple, heterogeneous targets [6].
Evidence before this study
According to the ESMO glossary, ‘targetable genomic alteration’
encodes an altered protein against which a drug exists or can
be synthesized and an ‘actionable genomic alteration’ includes
both targetable alterations and genomic alterations that cannot
be directly targeted but that leads to dysregulation of a path-
way in which there are possible targets.
According to Galot et al. the percentage of patients in a bio-
marker driven trial that had an ‘actionable genomic alteration’
identified through screening programs ranged from 46% to 63%.
However, the number of patients who were finally treated with
a matched targeted therapy across three international trials
was low: 13%, 16%, and 19% respectively [7]. It was 27% in a
most recent trial publication, probably related to the extension
of the screening panels. Different reasons explain these low
enrolment rates: tumour tissue issues, rapid decline in the
patients’ performance status in line with rapidly progressing
disease, possibly related to a multiplicity of driver alterations,
the non-detection of a targetable alteration or the limitations of
access to relevant drugs. With pre-planned access, still only
12% of the patients were finally enrolled in a recently published
trial - only 18% of the screened tumours had been found to
have a genomic alteration that matched one of the 30 treat-
ment arms [7,8].
The summary on present achievements of biomarker-driven
studies is the low number of patients who benefit from this
approach. This suggests that for heterogeneous cancers with
multiple potential oncogenic drivers, biomarkers assessed only
at the DNA level in a panel assay, may 1/ not establish the main
tumour drivers and, 2/ not reliably predict drug responses. For
that reason, we took-into-account not only the genotype but
also the phenotype (e.g. gene expression/proteomic profiles) of
cancer cells as well as the multiplicity of potential driver altera-
tions. We initiated BioRAIDs, a supervised longitudinal study
with pretreatment cervical cancer sample collection and clini-
cal annotation (NCT02428842) [9]. PIK3CA mutations and/or
gene amplifications were the most frequently diagnosed onco-
genic alteration, present in 40% of BioRAIDs patients [2]. The
most frequently diagnosed suppressor gene alterations were
loss-of-function (LOF) mutations in KMT2A-D (Lysine methyl
transferase) gene leading to defective histone H3K4 methyla-
tion. The cumulative frequency of tumours harboring any sup-
pressor gene alterations in the epigenetic pathway (involving
KMT2C, KMT2D, EP300, ARID1A, ARID2, ATRX, CREBBP, KMT2A,
KDM5C) was 45% of which 32% also had alterations in PI3KCA.
Added value of this study
While current treatment strategies are still mostly based on
tumour location and disease stage and very few on tumour
biology [10], we set out to identify upfront the molecular alter-
ations that will need innovative therapies by assessing a Euro-
pean cervical cancer patient population. To do this, we tested
the lead molecular alterations based not only on DNA altera-
tions but also on activated protein expression profiles
associated with cure or progression following standard
(chemo-radiation) therapy. Molecular testing for multiplicity of
driver alterations was carried out on a supervised patient popu-
lation with pre-therapy frozen and fixed tumour biopsies as
well as six-monthly liquid biopsies, allowing to follow viral
presence and persistent molecular alterations over time
(NCT02428842). A boosting implementation of Cox models,
compatible with high-dimensional settings, allowed to inte-
grate relevant information on molecular variants (based on
whole exome sequencing (WES)), copy number variations as
well as reverse phase protein arrays (RPPA), together with clini-
cal data. From our dedicated biomarker screening trial, we
identified 16 molecular alterations (based on WES analysis)
and 30 activated proteins to be associated with progression-
free survival up to 24 months following standard chemo-radia-
tion. Patients with two or more actionable genomic alteration,
previously associated with poor outcome, progressed earlier.
Most significant beneficial markers (ATRX, MED13) may serve
as biomarkers in favor of chemo-radiation, while most recur-
rent deleterious markers (TP53 and CREBBP) suggest the need
for additional innovative therapies.
Implication of all the available evidence
The present findings are to our knowledge the first systematic
approach towards the understanding of multiple governing
alterations in cervical cancer, treated by the current best stan-
dard clinical approach, which has been developed in careful
clinical trials over the past decades.
Integration of individual tumour specific constellations
based on multiple tumour cell genotypic and phenotypic driver
alterations with outcome data leads to a better understanding
of relevant mechanisms that govern clinical control (or not) of
cervical cancer treated by chemo-radiation.
Pre-treatment awareness of type and constellation of dele-
terious genetic alterations will assist the design of innovative
umbrella type platform trials.
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Cervical cancer (CC) remains, after breast cancer, the second most
common malignancy in women [11]. Although patients with CC
exhibit differences in their clinical course, infection by high-risk
Human Papilloma Virus (HPV) remains an important initiating event
in CC tumourigenesis [12], and one of the most important risk factors
for developing CC [13]. The global incidence is approximately 500 000
cases per year and the mortality of this virally initiated disease is in
the order of 50% of patients worldwide [11]. Advances in biomarker-
driven cancer therapy development are hampered by the complexity
of the human genome and the high inter- and intra-patient variability
in molecular alterations.
BioRAIDs, a supervised longitudinal study with pretreatment sam-
ple collection and clinical annotation (NCT02428842) [9] allowed the
identification of molecular pathways related to poor outcome. PIK3CA
mutations and/or gene amplifications were the most frequently diag-
nosed oncogenic alteration, present in 40% of BioRAIDs patients. The
most frequently diagnosed suppressor gene alterations were loss-of-
function (LOF) mutations in KMT2A-D (Lysine methyl transferase)
genes leading to defective histone H3K4 methylation. The cumulative
frequency of tumours harboring any suppressor gene alterations in
the epigenetic pathway (involving KMT2C, KMT2D, EP300, ARID1A,
ARID2, ATRX, CREBBP, KMT2A, KDM5C) was 45% of which 32% also had
alterations in PI3KCA [2].
The present manuscript attempts to further detail the relevance
of specific molecular alterations. The relative impact of individual
S.M. Scholl et al. / EBioMedicine 61 (2020) 103049 3markers on CC response and outcome following chemo-radiation was
assessed using an integrative approach.
2. Materials and methods
2.1. Patients
Patients included in this study had been enrolled in the EU-
funded prospective CC BioRAIDs study (NCT02428842) run by the
RAIDs Network (Rational Molecular Assessment and Innovative Drug
Selection, www.raids-fp7.eu). The clinical protocol together with
tumour sampling procedures, quality control of samples and treat-
ment was conducted in 18 European centers from seven European
countries. Study results have been previously published [2,9,14]. The
study has been conducted in accordance with the ethics principles of
the Declaration of Helsinki and a signed informed consent for the
participation in the study was a prerogative. All patients had pre-
treatment mandatory frozen tumour, blood and serum sampling as
well as mandatory magnetic resonance imaging. Pet scan imaging
was optional and is available in half of the population. Genomics
analyses on patient derived samples have already been published [2].
Several data-frames were compiled to ask or validate specific ques-
tions, based on shared patients and data types. Four subpopulations
for whom omics and reverse phase protein array (RPPA) data are
available were considered more specifically in this manuscript: 181
pts with mutation data (Supplementary Table 1), 146 with mutation
and copy number variation (CNV) data, 135 with RPPA data and 89
patients with full molecular profile (Table 1 and Fig. 1).
2.2. DNA sequencing & bioinformatics
Paired-end whole exome sequencing (WES) and paired-end tar-
geted gene panel sequencing were performed on a HiSeq2500 plat-
form. The sequencing was performed to reach an average depth of
coverage of ~150 £ for whole exome sequencing and ~730 £ for tar-
geted sequencing. The data were further processed by the Institut
Curie bioinformatics pipeline. Somatic alterations (point mutations,
insertions/deletions and copy number changes) were identified (Sup-
plementary Table 2) from the aligned sequences of matched-samples
using dedicated tools, detailed in Scholl et al. [2]
CoxBoost analysis [15] was used to fit a Cox proportional hazards
model by component wise likelihood-based-boosting. This type of
analysis is suited for models with high number predictors, typically
omics covariates. Analysis was limited to previously curated gene
variants of documented clinical significance. The analysis further-
more focused on molecular alterations that were detected in a sizableTable 1
Patients’ characteristics of the different BioRAIDs subpopulations.
Clinical data Mutation data
Number of patients 376 181
FIGO 2018 I/II 290 (77%) 133 (73%)
III/IV 86 (23%) 48 (27%)
PFS Event 108 (29%) 60 (33%)
HPV Clade Clade 7/HPV negative 104 (28%) 54 (30%)
Clade 9/Others 220 (58%) 126 (70%)
NA 52 (14%) 1 (<1%)
Histology Squamous 308 (82%) 148 (82%)
Adenocarcinoma 43 (11%) 19 (10%)
Adenosquamous 15 (4%) 11 (6%)
Mixed/undifferentiated. 9 (2%) 3 (10%)
NA 1 (<1%) 0
Initial Treatment Chemoradioation 242 (64%) 112 (62%)
Surgery 76 (20%) 35 (19%)
NACT 58 (15%) 34 (19%)
CNV= copy number variation; FIGO 2018 integrating lymph nodes status under I
Clade 9 (HPV 16.31.33.35.52.58) & Clade 7 (HPV 18.39.45.59.68); NACT=Neaodjuvaproportion of patients (>5%), to ensure estimation of the stability and
relevance of the procedure.
2.3. Reverse phase protein array (RPPA)
For RPPA analyses, the samples were processed as previously
described [16] and printed onto nitrocellulose covered slides (Super-
nova, Grace Biolabs) using a dedicated arrayer (2470 arrayer, Aushon
Biosystems). Five serial dilutions, starting at 2000mg/ml and two tech-
nical replicates per dilution were printed for each sample. Arrays were
labeled with 194 specific, or without primary antibody (as negative
control), as described previously described [16]. All primary antibodies
used in RPPA have been previously tested by Western Blotting to
assess their specificity for the protein of interest. Raw data were nor-
malized using Normacurve [17], which normalizes for fluorescent
background per spot, a total protein stain and potential spatial bias on
the slide. Next, each RPPA slide was median centered and scaled
(divided bymedian absolute deviation). We then corrected for remain-
ing sample loading effects individually for each array by correcting the
dependency of the data for individual arrays on the median value of
each sample, over all 194 arrays, using a linear regression.
3. Statistical analysis
The endpoint of interest is progression-free survival (PFS), defined
as the minimal time of relapse or death, with administrative censor-
ing at 24 months. All analyses were performed using R version 3.6.1
software.
4. Role of funders
The funders had no role in study design, data collection, data analysis,
interpretation or writing of the report.
5. Results
Patient characteristics with a complete dataset (n = 89)
Clinical and patho-biological covariates on the complete BioRAIDS
population (n = 376) have been previously published [2].
Here we focused first on a patient population (n = 89) with com-
plete information for all data types (mutations, amplifications/dele-
tions and protein expression and phosphorylation patterns). For
subsets of the initial population (Table 1), there were no significant
changes in treatment allocation or in clinical and patho-biological
parameters such as FIGO-2018 stage (I-II vs III-IV), HPV typeMutation and CNV data RPPA data Mutation, CNV and RPPA data
146 135 89
110 (75%) 97 (72%) 66 (74%)
36 (25%) 38 (28%) 23 (26%)
50 (34%) 46 (34%) 32 (36%)
41 (28%) 42 (31%) 27 (30%)
104 (71%) 93 (69%) 62 (70%)
1 (<1%) 0 0
118 (81%) 112 (83%) 72 (81%)
16 (11%) 15 (11%) 11 (12%)
9 (6%) 7 (5%) 5 (6%)
3 (2%) 1 (<1%) 1 (1%)
0 0 0
89 (61%) 89 (66%) 55 (62%)
30 (21%) 21 (16%) 16 (18%)
27 (18%) 25 (19%) 18 (20%)
IIC; PFS=Progression free survival; HPV type (based on hybridisation test)2:
nt chemotherapy, NA=not available.
Fig. 1. Venn diagram illustrating the number of patients for the different combinations
of omics types and clinical data. (CNV = copy number variation; RPPA = reverse phase
protein array).
4 S.M. Scholl et al. / EBioMedicine 61 (2020) 103049{negative and viral clade 7 (HPV18,39,45,59,68) as opposed to viral
clade 9 (HPV 16,31,33,35,52,58)}. While 6266% of patients were
allocated to chemo-radiation as a first treatment, many patients hadFig. 2. Coefficient values in Cox boost of frequent genetic variants associated with worse or b
RRPA variables) clinical data (panel a); clinical data with RPPA variables (panel b); gene
(mut = mutations; CNV = copy number variations; RPPA = reverse phase protein array).external beam radiation with or without platinum or brachytherapy
as a follow-on treatment after surgery or neoadjuvant chemotherapy.
This led to close to 90% of patients having received radiation therapy
as previously published [2].
5.1. Prognostic biomarkers for standard treatment in CC: integrating
clinical, mutations, CNV, as well as activated protein expression
Using this complete cohort of 89 patients, the CoxBoost approach
provides non-zero ranked biomarker effect estimates summarized in
(Fig. 2a). A positively weighted biomarker in this test corresponds to
a higher risk of event occurrence as measured by PFS and therefore
represents a deleterious biomarker.
When RPPA data were factored into the CoxBoost analysis of
mutations and copy number variants in a patient population with
information for all omics types, a number of activated phospho-pro-
teins outranked molecular alterations. Intriguingly, beta-catenin,
when phosphorylated in Ser552 (pb-Cat552), ranked highest as a
better prognosis indicator, while another post translationally modi-
fied form (pb-Cat675) of the same protein, ranked second highest for
worse prognosis. Protein 1433 b, an abundant chaperon protein
and supposedly responsible for pb-Cat552 nuclear exit [18], ranked
highest for worse prognosis (Fig. 2a).
When patients with genetic variants together with copy number
variations (n = 146; Fig. 2c) or genetic variants only (n = 181, Fig. 2d)
were analyzed separately, other genetic markers with significant
alterations for outcome based on WES were detected. Genetic var-
iants consistently associated with better prognosis were alterationsetter prognosis using all available omics types (mutational, copy number variation and
and copy number variants and mutations (panel c) and mutations only (panel d).
S.M. Scholl et al. / EBioMedicine 61 (2020) 103049 5in ATRX and MED13, while LOF of TP53 and CREBBP remained the
dominant genetic parameters, significantly associated with worse
prognosis. Only variants represented in at least 5% of patients were
tested. A better prognosis was associated with significant alterations
in the following genes: FBXW7, KMT2C (MLL3) while alterations in:
CSMD3, UBR5, PIK3CA, NOTCH1, NFE2L2, ARID1A, KMT2D (MLL2), and
PTENwere associated with a higher risk for recurrence.
5.2. Phosphorylation patterns in b-Cat at ser552 is a good prognostic
indicator in an enlarged patient population (n = 135)
To confirm these protein activation-related findings, we focused
on a patient set of 135 patients with data on both clinical outcome
and on RPPA expression (Fig. 2b). Furthermore, looking at the previ-
ously identified RPPA clusters [2], pb-Cat552 appeared significantly
less expressed in the EMT cluster, as compared to the two other clus-
ters (Fig. 3a), lending credence to its relevance as a good prognostic
indicator. Protein 1433 b appeared significantly enriched in the
“DNA damage signaling” cluster (Fig. 3b). In addition, no association
was found between the levels of IDO protein (Fig. 3c) or the pb-Cat675
form (Fig. 3d) with any of the three clusters.
5.3. Tumour genetic heterogeneity and timing of recurrence
Patients with co-occurences of several deleterious genetic
markers (previously identified as associated with worse prognosis in
Fig. 2) were grouped according to the number of mutations they
carry. Mutations could be inferred from a population of 181 patients
(as shown in Fig. 1 and 2d) and mutations (only) were taken-into-
account in this analysis. Kaplan Meier survival curves, based on theFig. 3. Expression levels of phosphobeta-catenin-Ser552 (panel a) and 1433 protein (number of the deleterious markers identified in a specific tumour,
with PFS estimates at 24 months showed that tumours carrying  2
of relevant genetic appeared to be at a higher risk for earlier recur-
rence, as compared to those with one or none of the previously docu-
mented clinically significant gene variants (Fig. 4, p-value=0.00037).
While the notion that tumour heterogeneity at start, carries a higher
risk, is already well established, these findings will be retested in
larger populations in the future to better define individual risk.
Several molecular alterations may co-exist and affect outcome in
individual patients (Fig. 5a and 5b). When we collated these various
genomic alterations associated with treatment resistance on a per
patient basis, a large fraction of the population (n = 53) had single
alterations. Alterations below the 5% frequency level have not been
accounted for. Among the single alterations, PIK3CA was dominant
with n = 33 cases. However, 48 (54%) patients had more than one of
those genes which ranked high for a poor prognostic signal.
6. Discussion
Recent estimations of benefit of biomarker-driven clinical studies
repeatedly document the low number of patients to have benefited
from this approach [7]. This suggests that, for heterogeneous cancers
with multiple potential oncogenic drivers, biomarkers assessed
mostly by alterations in a limited gene panel at the DNA level, may
not be able to predict drug responses reliably. Molecular alterations
in cancer tissues have profound effects on RNA expression, which in
turn lead to modifications in protein expression and activation pat-
terns. Integrating WES and RPPA data and using a CoxBoost analysis
for progressive enrichment of biomarkers, we identified 16 molecular
alterations and 30 activated proteins that were associated with goodpanel b), IDO (panel c) and phosphobeta-catenin-Ser675 (panel d) per RPPA cluster.
Fig. 4. Kaplan Meier progression free survival curves as a function of tumour heterogeneity at start (number of mutations per patients from a defined list of genes), limited to the
following molecular alterations that were detected in a sizable proportion of patients (>5%). The probability of survival is the probability that the members of each group did not
experience death or relapse at each time point.
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dard chemo-radiation. Furthermore, patients diagnosed with two or
more of these molecular alterations progressed earlier. The present
integration of genotype and phenotype led to a highly interesting
finding, namely that two different post-translational modifications of
the same protein: beta-catenin, exhibit opposite effect on the PFS.
In agreement with the present integrative results, what is the
published evidence that alterations in ATRX, MED13, and possibly
CASP8 (LOF) (Fig. 2) might render tumour cells more sensitive to this
treatment?
ATRX: This gene was first discovered as the genetic cause of the
a-thalassemia, mental retardation, X-linked (ATRX) syndrome
[19,20]. It is required for efficient replication of a subset of genomic
loci and involved in maintaining telomere structural integrity in
embryonic stem cells [21]. ATRX has thus important cellular func-
tions, being involved in meiotic spindle organization, DNA repair,
chromatin organization and remodeling as well as nucleosome
assembly [21]. ATRX loss was shown to induce genomic instability
[22] and ATRX-deficient mouse tumours were shown to be highly
aggressive. Nevertheless, a better response to immune check point
inhibitors was observed in mice harboring ATRX-deficient tumours
[22]. ATRX gene mutations have also been associated with good prog-
nosis by extensive studies in neural tumours like gliomas and neuro-
blastoma, but, to our knowledge, no studies with respect to ATRX
and cervical cancer are presently available. Thus, this finding in cervi-
cal carcinoma is of high interest [23].
MED13 in association with MED12, CDK8, and Cyclin C constitutes
a four-subunit “kinase” module that exists in variable association
with a 26-subunit Mediator core [24]. Genetic and biochemical stud-
ies have established the Mediator kinase module to function in devel-
opmental and oncogenic signaling through Mediator, and much of itsfunction in signal-dependent gene regulation is thought to derive
from its resident CDK8 kinase activity which has been also been
linked to Wnt signaling [25,26,27]. Mediator is recruited to pro-
moters by transcriptional activators or nuclear receptors (ER, AR
among others) to induce gene expression and serves as a scaffold for
the assembly of a preinitiation complex. The mediator function is
involved in the regulated transcription of nearly all RNA polymerase
II-dependent genes [25,28]. Mediator functions as a bridge to convey
information from gene-specific regulatory proteins to the basal RNA
polymerase II transcription machinery. Beyond CDK8, little is pres-
ently known regarding the functional convergence and divergence
related to MED12/12 L and MED13/13 [24]. However, genetic abla-
tion of MED12 or MED13 in mice similarly conferred early embryonic
lethality, excluding the possibility of functional redundancy among
their corresponding paralogs during development [25]. These data
are in line with the present results suggesting that cancer cell loss of
MED13 function might increase susceptibility to cancer cell damage
by chemo-radiation.
Caspase-8 has been originally identified as an essential player of
death receptor-induced apoptosis. Emerging evidence suggested that
the retention of caspase-8 in glioblastoma may interfere with the sen-
sitivity to radio and chemotherapeutic approaches through multiple
pathways, including improvement of the DNA damage repair and the
activation of NF-kB and cytokine production. Caspase-8 contributes
to the functionality of the DNA damage response. Caspase-8 LOF on
the other hand promotes genomic instability and tumour develop-
ment. Intriguingly, it has been suggested that the inhibition of Cas-
pase-8, although detrimental for apoptosis induction, may enhance
the sensitivity of cancer cells to DNA damaging agents, most likely
independent of apoptosis, and may therefore represent a valuable
therapeutic strategy [29]. Loss of Caspase-8 function was associated
Fig. 5. Pattern of frequencies of molecular alterations of significance by individual patient. Panel a with mutations only and Panel b integrating mutations and CNV.
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neck squamous cell carcinoma [4]. As a result, tumours with loss of
Caspase-8 function may be more likely to benefit from chemoradia-
tion, in accordance with the present results, while they might not be
sensitive to immune checkpoint inhibition.
While alterations in ATRX, MED13 and CASP8 were association
with treatment response, our results suggested that LOF alterations
in TP53 and CREBBP may be top ranking markers that impact cervical
cancer cells to resist chemo-radiation.
TP53: In physiological conditions, the encoded p53 protein
responds to cellular stresses by inducing cell cycle arrest, apoptosis,
senescence, DNA repair, or changes in metabolism. In the present
patient cohort, the TP53 bi-allelic gene loss was highly detrimental
but present at a low frequency, in opposition to other malignancies
such as in head/neck squamous cell carcinomas (HNSCC), or high
grade serous carcinoma of the ovary, which are primarily driven by
complete loss of the gene TP53. In HNSCC, a subgroup of patients
with dismal prognosis after chemoradiation was characterized by
TP53 mutations. The prognostic impact was stronger for nonsense/
frameshift TP53 mutations associated with either expression of a
truncated p53 protein or complete loss of p53 expression compared
with missense mutations resulting in overexpression of mutated p53
[30]. Similarly, in diffuse intrinsic pontine gliomas (DIPG),inactivation by mutation of TP53 was shown to contribute to radio-
resistance [31]. In cervical cancer, the p53 protein is more commonly
ubiquitinated and degraded by HPVE6, leading to carcinogenesis.
While the HPV virus mediated inactivation of TP53 protein, together
with the inactivation of RB (retinoblastoma) protein by HPVE7, are
the most frequent driver protein alterations in cervical cancer, only
the cervical cancer patients with a complete bi-allelic TP53 gene loss
had a dismal prognosis. Furthermore, HPV positivity and TP53 loss
are mutually exclusive patterns in cervical cancer patients (Kamal
et al., submitted).
Novel cancer therapeutics that supposedly reactivate a variant
tumour p53 protein include small molecule drug candidates (such
as APR-246), presently in clinical development for myelodysplastic
syndromes, acute myeloid leukemia, as well as solid tumours
(NCT03268382) [32]. A phase Ib/II clinical trial in TP53 mutated
high-risk hematological cancers is ongoing, combining APR-246
and azacytidine (NCT03931291). Such a combination might be
worth considering for chemoradiation resistant cervical cancer
patients with loss of function in both p53 and epigenetic regulating
genes.
CREBBP was first isolated as a nuclear protein that binds to cAMP-
response element binding protein (CREB), and together with EP300 was
shown to encode lysine acetyl-transferases (KAT) with critical roles in
8 S.M. Scholl et al. / EBioMedicine 61 (2020) 103049embryonic development, growth control, and homeostasis by coupling
chromatin remodeling to transcription factor recognition [33].
CREBBP alterations have been documented in many cancers, and
specifically in 5% of SCC of the uterine cervix [30], which is compara-
ble to the 8% LOF by mutation or non-frame-shift deletion, reported
here. CREBBP loss in lung cancer was shown to reduce histone acety-
lation and transcription of cellular adhesion genes, while driving
tumorigenesis [34]. These effects could be partially restored by HDAC
inhibition, which exhibited enhanced effectiveness in CREBBP-
deleted tumours, suggesting a role for treatment by a HDAC inhibitor
such as Vorinostat, while CREBBP/EP300 bromo‑domain inhibitors
are also under investigation [35].
In a previous publication, we had tested the relative role of PIK3CA
alone or PIK3CA and a “metagene” of epigenetic regulators. While
PIK3CA alone did not carry a bad prognosis, it did so in association
with alterations in epigenetic regulators [2]. Fig. 5 details the patients
with single or multiple molecular alterations (above the 5% frequency
level) that were present in the population. These results may assist to
define the patient population for future molecular targeting.
Two different post-translational modifications on beta-catenin
appeared to be high-profile parameters related to outcome, with
opposite prognosis, depending on the protein isoform as distin-
guished by its specific phosphorylation pattern. The supposedly
active nuclear form of beta catenin, which according to Goretsky
et al. [18], is phosphorylated in Ser 552 (pb-Cat552) appeared
associated with good outcome, while the predominance of a phos-
phorylated epitope in Ser 675 (pb-Cat675), which is located just
outside the armadillo repeat at the beginning of the C terminal
domain, was associated with poor outcome in our dataset. Trunca-
tions in this C terminal domain was shown to lead to loss of function
[36]. Crystallographic studies have suggested that binding of E-cad-
herin or APC occurs in the armadillo structure, whereas helix C (con-
taining Ser 675) appears to interact with Chibby and ICAT (alias
CTNNBIP1), which is a physiological inhibitor of Wnt signals that
prevents the binding of TCF to beta catenin [37]. Of interest is the
finding that high protein 1433 expression which cooperates
with Chibby to regulate subcellular distribution and signaling activ-
ity [38] in the CoxBoost analysis came up close together and on the
same side with the high levels in the Helix C (pb-Cat675) chain. We
confirmed our results on a larger patient population (n = 135) for
whom RPPA and clinical, but not genetic data, were presently avail-
able. Furthermore, the (pb-Cat552) isoform associated with
response to chemoradiation was inversely correlated with the RPPA
cluster of proteins associated with EMT. Our findings, based on qual-
ity controlled fresh frozen clinical samples, were puzzling in view of
the experimentally derived data by Goretsky et al. [18] who sug-
gested that, during Wnt-activated signaling, beta-catenin undergoes
partial site-directed cleavage prior to a nuclear localization of a low
molecular weight form (LMW) which is supposedly the pb-Cat552
isoform. Furthermore their findings suggested that the LMW pb-
Cat552 isoform supposedly binds transcription factor 4 (TCF4) and
drives transcription in chromatin-bound fractions. Overexpression
in vitro of a double truncated form of beta-catenin, (reducing it to
the LMW form), enhanced transcriptional activation, cell prolifera-
tion and growth of tumour xenografts, while a substitution of Ser
552 to Alanine abrogated all these effects.
Wnt-activated signaling is commonly associated with cancer pro-
gression. However, if pb-Cat552 is indeed associated with cell prolif-
eration, as suggested by Goretsky et al., cells overexpressing pb-
Cat552 are likely to be more sensitive to chemo-radiation and thus
be associated with a better prognosis in this population treated by
chemo-radiation. Moreover, according to our biostatistics analysis,
pb-Cat552 was lower in the EMT cluster, and EMT is often a hallmark
of stem cells that proliferate less and are resistant to chemo-radia-
tion. While cancer cells are thought to proliferate and to invade, it is
tempting to speculate that the pb-Cat552 phosphorylation formmight specifically orientate towards proliferation and not invasion,
while the predominance of the pb-Cat675 form might be more per-
missive to invasion. The bioinformatics analysis does not associate
this latter form with any of the RPPA clusters, but it is not anti-corre-
lated with EMT. In cancer cells, many additional alterations are at
play and inactivation of UBR5 (an E3 ligase), normally directing the
beta-catenin protein to the proteasome pathway, may be of rele-
vance. Alternatively, similarly to the accumulation of a non-func-
tional defective p53 protein in the case of LOF TP53 mutations, pb-
Cat552 might accumulate when it cannot function and/or resist deg-
radation, or degradation enzymes may be inactive. While the subcel-
lular location of the activated protein forms of beta-catenin as well as
their functionality and their kinetics remain to be assessed in the con-
text of cancer treatment, different drugs relevant to target aberrantly
active beta-catenin signaling have been suggested, such as Bortezo-
mib [18]. Wnt pathway targeting has also been recently reviewed in
a context of head and neck squamous cell carcinoma [39]. Further-
more, evidence from a human retinal epithelial cell model showed
silencing of endogenous TF (tissue factor) to significantly suppress
the Wnt/b-catenin signal transduction cascades, suggesting that the
regulation of TF on VEGF expression may be mediated by activation
of the Wnt/b-catenin signaling pathway [40]. Tisotumab Vedotin,
directly targets tissue factor and was shown safe and effective in
SCCC [41]. Targeted therapy towards TF and Wnt signaling and its
downstream proteins is promising for interventions of pathological
processes involving TF-regulated angiogenesis and inflammation.
IDO (indole amine 2,3 oxygenase) is thought to play a role in a
variety of pathophysiological processes such as antimicrobial and
anti-tumour defense, neuropathology, immunoregulation and anti-
oxidant activity. This enzyme catalyzes the first step of the catabolism
of the essential amino acid tryptophan along the kynurenine pathway
[42]. In addition, through its expression in dendritic cells, monocytes,
and macrophages, this enzyme modulates T-cell behavior by its
peri‑cellular catabolization of the essential amino acid tryptophan.
IDO is thought to act either as a suppressor of anti-tumour immunity
or involved in anti-tumour defense while high IDO in the present
analysis was an important predictor of good prognosis in the context
of response to chemo-radiation therapy [43,44]. Furthermore, muta-
tions in the gene UBR5 (Ubiquitin Protein Ligase E3 Component N-
Recognin 5) was associated with poor prognosis. Since IDO is an
important enzyme in the tryptophan metabolism and the gene UBR5
being related to tryptophan metabolism, these two factors might
contribute to radiation-induced immune check point activation
which could potentially affect the response to radiation [45].
In conclusion, this is to our knowledge the first omics derived
evidence for the relevance of two different post translationally modi-
fied forms of beta-catenin as potential biomarkers for chemo-radia-
tion. Our data is consistent with the idea shared by others [46,38]
that beta-catenin expression/activation together with p53 [30] and
epigenetic alterations (in particular CREBBP and possibly UBR5,
CSMD3, KMT2D) may be at the heart of cervical cancer control/pro-
gression. The relevance of Wnt pathway activity and CTNNB1 muta-
tions and activations in cancer is not new, but elucidation of the
intimate control mechanisms, leading to the nuclear translocation of
an active form, is recent and our findings call for additional mecha-
nistic studies, on post-translational modifications of beta catenin
together with cell invasive behavior.
Our study comes with some limitations, notably the need for vali-
dation in larger cohorts with clinical, molecular alterations, con-
jointly with protein expression/activation. The reproducibility of the
set of biomarkers identified by the boosting approach will be under
further scrutiny. Large aggregated studies are mandatory to confirm
relevant constellations of molecular alterations and decipher multiple
functional drivers that can be targeted. Focus on individual patient-
specific molecular information will lead to innovative combined
treatments to be explored in umbrella type platform trials.
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[5] Le Tourneau C, Delord J-P, Gonçalves A, Gavoille C, Dubot C, Isambert N, et al.
Molecularly targeted therapy based on tumour molecular profiling versus con-
ventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-
of-concept, randomised, controlled phase 2 trial. Lancet Oncol 2015 Oct;16
(13):1324–34.
[6] McGranahan N, Swanton C. Clonal Heterogeneity and Tumor Evolution: past,
Present, and the Future. Cell 2017;168(4):613–28 09.
[7] Galot R, Le Tourneau C, Guigay J, Licitra L, Tinhofer I, Kong A, et al. Personalized bio-
marker-based treatment strategy for patients with squamous cell carcinoma of the
head and neck: EORTC position and approach. Ann Oncol 2018;29(12):2313–27 01.
[8] Flaherty K.T., Gray R., Chen A., Li S., Patton D., Hamilton S.R., et al. THE MOLECU-
LAR ANALYSIS FOR THERAPY CHOICE (NCI-MATCH) TRIAL: LESSONS for GENOMIC
TRIAL DESIGN. J Natl Cancer Inst [Internet]. [cited 2020 Apr 23]; Available from:
https://academic.oup.com/jnci/advance-article/doi/10.1093/jnci/djz245/5699915
[9] Ngo C, Samuels S, Bagrintseva K, Slocker A, Hupe P, Kenter G, et al. From prospec-
tive biobanking to precision medicine: bIO-RAIDs  an EU study protocol in cervi-
cal cancer. BMC Cancer [Internet] 2015 Nov 4:15. [cited 2020 Apr 23]Available
from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4632364/.
[10] Nagarkar R, Patil D, Crook T, Datta V, Bhalerao S, Dhande S, et al. Encyclopedic
tumor analysis for guiding treatment of advanced, broadly refractory cancers:
results from the RESILIENT trial. Oncotarget 2019 Sep 24;10(54):5605–21.
[11] Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer inci-
dence and mortality worldwide: sources, methods and major patterns in GLOBO-
CAN 2012. Int J Cancer 2015 Mar 1;136(5):E359–86.
[12] Schiffman MH, Bauer HM, Hoover RN, Glass AG, Cadell DM, Rush BB, et al. Epide-
miologic evidence showing that human papillomavirus infection causes most cer-
vical intraepithelial neoplasia. J Natl Cancer Inst 1993 Jun 16;85(12):958–64.
[13] Wentzensen N, Vinokurova S, von Knebel Doeberitz M. Systematic review of
genomic integration sites of human papillomavirus genomes in epithelial dyspla-
sia and invasive cancer of the female lower genital tract. Cancer Res 2004 Jun
1;64(11):3878–84.
[14] Samuels S, Balint B, von der Leyen H, Hupe P, de Koning L, Kamoun C, et al. Preci-
sion medicine in cancer: challenges and recommendations from an EU-funded
cervical cancer biobanking study. Br J Cancer 2016 Dec 6;115(12):1575–83.
[15] Binder H, Schumacher M. Allowing for mandatory covariates in boosting estima-
tion of sparse high-dimensional survival models. BMC Bioinformatics 2008 Jan
10;9(1):14.
[16] Meseure D, Vacher S, Lallemand F, Alsibai KD, Hatem R, Chemlali W, et al. Prog-
nostic value of a newly identified MALAT1 alternatively spliced transcript in
breast cancer. Br J Cancer 2016 14;114(12):1395–404.
[17] Troncale S, Barbet A, Coulibaly L, Henry E, He B, Barillot E, et al. NormaCurve: a
SuperCurve-based method that simultaneously quantifies and normalizes reverse
phase protein array data. PLoS ONE 2012;7(6):e38686.
[18] Goretsky T, Bradford EM, Ye Q, Lamping OF, Vanagunas T, Moyer MP, et al. Beta-cate-
nin cleavage enhances transcriptional activation. Sci Rep 2018 Jan 12;8(1):1–15.
[19] Gibbons RJ, Picketts DJ, Villard L, Higgs DR. Mutations in a putative global tran-
scriptional regulator cause X-linked mental retardation with alpha-thalassemia
(ATR-X syndrome). Cell 1995 Mar 24;80(6):837–45.
[20] Wada T, Kubota T, Fukushima Y, Saitoh S. Molecular genetic study of japanese
patients with X-linked alpha-thalassemia/mental retardation syndrome (ATR-X).
Am J Med Genet 2000 Sep 18;94(3):242–8.
[21] Watson LA, Goldberg H, Berube NG. Emerging roles of ATRX in cancer. Epigenom-
ics 2015;7(8):1365–78.
[22] Koschmann C, Calinescu A-A, Nunez FJ, Mackay A, Fazal-Salom J, Thomas D, et al.
ATRX loss promotes tumor growth and impairs nonhomologous end joining DNA
repair in glioma. Sci Transl Med 2016 Mar 2;8(328) 328ra28.
[23] Fazal Salom J, Bjerke L, Carvalho D, Boult J, Mackay A, Pemberton H, et al. PDTM-
33. ATRX LOSS CONFERS ENHANCED SENSITIVITY TO COMBINED PARP INHIBI-
TION AND RADIOTHERAPY IN PAEDIATRIC GLIOBLASTOMAMODELS. Neuro Oncol
2018 Nov 5;20(suppl_6):vi210–1.
[24] Bourbon H-M. Comparative genomics supports a deep evolutionary origin for the
large, four-module transcriptional mediator complex. Nucleic Acids Res 2008
Jul;36(12):3993–4008.
[25] Clark AD, Oldenbroek M, Boyer TG. Mediator kinase module and human tumori-
genesis. Crit Rev BiochemMol Biol 2015;50(5):393–426.
[26] Firestein R, Bass AJ, Kim SY, Dunn IF, Silver SJ, Guney I, et al. CDK8 is a colorectal
cancer oncogene that regulates b-catenin activity. Nature 2008 Sep 25;455
(7212):547–51.
[27] Li J, Li X, Kong X, Luo Q, Zhang J, Fang L. MiRNA-26b inhibits cellular proliferation
by targeting CDK8 in breast cancer. Int J Clin Exp Med 2014;7(3):558–65.
[28] Tsai K-L, Sato S, Tomomori-Sato C, Conaway RC, Conaway JW, Asturias FJ. A con-
served Mediator-CDK8 kinase module association regulates Mediator-RNA poly-
merase II interaction. Nat Struct Mol Biol 2013 May;20(5):611–9.
[29] Boege Y, Malehmir M, Healy ME, Bettermann K, Lorentzen A, Vucur M, et al. A
Dual Role of Caspase-8 in Triggering and Sensing Proliferation-Associated DNA
Damage, a Key Determinant of Liver Cancer Development. Cancer Cell 2017 11;32
(3) 342-359.e10.
10 S.M. Scholl et al. / EBioMedicine 61 (2020) 103049[30] Tinhofer I, Stenzinger A, Eder T, Konschak R, Niehr F, Endris V, et al. Targeted
next-generation sequencing identifies molecular subgroups in squamous cell car-
cinoma of the head and neck with distinct outcome after concurrent chemoradia-
tion. Ann Oncol 2016;27(12):2262–8.
[31] Werbrouck C, Evangelista CCS, Lobon-Iglesias M-J, Barret E, Teuff GL, Merlevede J,
et al. TP53 pathway alterations drive radioresistance in Diffuse Intrinsic Pontine Glio-
mas (DIPG). Clin Cancer Res [Internet] 2019 Jan 1 [cited 2020 Jun 22]. Available from:
https://clincancerres.aacrjournals.org/content/early/2019/08/31/1078-0432.CCR-19-
0126.
[32] Gourley C, Green J, Gabra H, Vergote I, Basu B, Brenton JD, et al. PISARRO: a EUTROC
phase Ib study of APR-246 in combination with carboplatin (C) and pegylated lipo-
somal doxorubicin (PLD) in platinum sensitive relapsed high grade serous ovarian
cancer (HGSOC). JCO 2016 May 20;34(15_suppl) 55715571.
[33] Attar N, Kurdistani SK. Exploitation of EP300 and CREBBP Lysine Acetyltransfer-
ases by Cancer. Cold Spring Harb Perspect Med 2017 Mar 1;7(3).
[34] Jia D, Augert A, Kim W, Eastwood E, Wu N, Ibrahim AH, et al. Crebbp Loss Drives
Small Cell Lung Cancer and Increases Sensitivity to HDAC Inhibition. Cancer Dis-
cov 2018;8(11):1422–37.
[35] Zou L, Xiang Q, Xue X, Zhang C, Li C, Wang C, et al. Y08197 is a novel and selective
CBP/EP300 bromodomain inhibitor for the treatment of prostate cancer. Acta
Pharmacol. Sin. 2019 Nov;40(11):1436–47.
[36] Cox RT, Pai LM, Kirkpatrick C, Stein J, Peifer M. Roles of the C terminus of Arma-
dillo in Wingless signaling in Drosophila. Genetics 1999 Sep;153(1):319–32.
[37] Xing Y, Takemaru K-I, Liu J, Berndt JD, Zheng JJ, Moon RT, et al. Crystal Structure of
a Full-Length b-Catenin. Structure 2008 Mar 11;16(3):478–87.[38] Li F-Q, Mofunanya A, Harris K, Takemaru K-I. Chibby cooperates with 14-3-3 to
regulate b-catenin subcellular distribution and signaling activity. J Cell Biol 2008
Jun 30;181(7):1141–54.
[39] Paluszczak J. The Significance of the Dysregulation of Canonical Wnt Signaling in
Head and Neck Squamous Cell Carcinomas. Cells 2020 Mar 15;9(3).
[40] Wang Y, Sang A, Zhu M, Zhang G, Guan H, Ji M, et al. Tissue factor induces VEGF
expression via activation of the Wnt/b-catenin signaling pathway in ARPE-19
cells. Mol Vis 2016;22:886–97.
[41] Hong DS, Concin N, Vergote I, de Bono JS, Slomovitz BM, Drew Y, et al. Tisotumab
Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer. Clin Can-
cer Res 2020 Mar 15;26(6):1220–8.
[42] Metz R, Duhadaway JB, Kamasani U, Laury-Kleintop L, Muller AJ, Prendergast GC.
Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of
the antitumor indoleamine 2,3-dioxygenase inhibitory compound 1-methyl-
tryptophan. Cancer Res 2007 Aug 1;67(15):7082–7.
[43] Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, et al. Evi-
dence for a tumoral immune resistance mechanism based on tryptophan degra-
dation by indoleamine 2,3-dioxygenase. Nat Med 2003 Oct;9(10):1269–74.
[44] van Baren N, Van den Eynde BJ. Tryptophan-degrading enzymes in tumoral
immune resistance. Front Immunol 2015;6:34.
[45] Kesarwani P, Prabhu A, Kant S, Kumar P, Graham SF, Buelow K, et al. Tryptophan
metabolism contributes to radiation-induced immune checkpoint reactivation in
glioblastoma. Clin Cancer Res 2018 Aug 1;24(15):3632–43.
[46] Kim S., Jeong S. Mutation Hotspots in the b-Catenin Gene: lessons from the
Human Cancer Genome Databases. 2019 Jan 7;42(1):816.
